Wednesday April 12, 9:31 am Eastern Time
Company Press Release
Sanguine Corp. Announces Agreement Which Signs Professor William Regelson, M.D., as Member of Sanguine Medical Advisory Board
Agreement Also Announces Regelson as Assistant to Chief Operating Officer Admiral Van Orden
PASADENA, Calif.--(BUSINESS WIRE)--April 12, 2000-- Sanguine Corp. (OTC BB: SGNC - news) Wednesday announced an agreement which signs Professor William Regelson, M.D., as a member of the Sanguine Medical Advisory Board and as an assistant to the Chief Operating Officer, Admiral Van Orden.
Dr. Regelson is a professor of Medicine at the Virginia Commonwealth University and has been a leading researcher in the field of aging and Alzheimer's Disease for over 20 years. Regelson has written or edited several books and texts that are available on the mass market, focusing his research on the causes of the decline of the human body.
Regelson's role is to identify PHER-O2 uses and implement research protocols and studies to prove PHER-O2's beneficial effects.
Regelson is particularly suited to this position as he has researched and written on the discovery of amyloid plaques in the brain, which are thought to impede proper cerebral oxygenation.
Regelson's paper, published in the annals of the New York Academy of Sciences in 1997, specifically hypothesizes the potential of PFCs, of which PHER-O2 is based, to oxygenate plaque-encased regions of the brain may be used to alleviate the symptoms of Alzheimer's Disease.
Regelson's numerous publications also include the following: Dehydroepiandrosterone, 1999; The Superhormone Promise: Nature's Antidote to Aging, 1997; The Melatonin Miracle: Nature's Age-Reversing, Disease-Fighting, Sex-Enhancing, 1995; Intervention in the Aging Process: Proceedings of the International Symposium on Intervention in the Aging Process, Boston, Nov. 5-6, 1982.
Regelson, a medical oncologist by specialty, will benefit the Sanguine team through his expertise in the study of Alzheimer's Disease, as well as the proposed cancer fighting effects associated with the oxygen tension created by PHER-O2.
Sanguine's PHER-O2 molecule contains 3-4 times the oxygen carrying capacity of human red blood corpuscles, thus enabling high concentrations of oxygen per unit volume.
Notice: This news release contains, and oral statements made from time to time by company representatives concerning the information contained herein may contain, so-called ``forward-looking statements.'
These statements can be identified with introductory words such as ``expects,' ``plans,' ``will,' ``estimates,' ``forecasts,' ``projects,' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing the company's growth strategy, operating and financial goals, regulatory submissions and approvals and development programs.
Many factors may cause actual results to differ from the company's forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
--------------------------------------------------------------------------------
Contact:
Sanguine Corp., Pasadena
Thomas C. Drees, 626/405-0079
Fax: 626/405-1041 |
